Use of immunomodulatory compounds for the treatment of disorders associated with endothelial dysfunction

Details for Australian Patent Application No. 2008325140 (hide)

Owner Celgene Corporation

Inventors Moutouh-De Parseval, Laure A.

Agent Phillips Ormonde Fitzpatrick

Pub. Number AU-A-2008325140

PCT Pub. Number WO2009/061445

Priority 61/002,411 08.11.07 US

Filing date 7 November 2008

Wipo publication date 14 May 2009

International Classifications

A61K 31/00 (2006.01)

A61K 31/366 (2006.01) - having six-membered rings, e.g. delta-lactones

A61K 31/454 (2006.01)

A61K 31/554 (2006.01) - having at least one nitrogen and at least one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem

A61K 45/06 (2006.01) Medicinal preparations containing active ingredients not provided for in groups

A61P 3/00 (2006.01) Drugs for disorders of the metabolism

A61P 3/10 (2006.01) Drugs for disorders of the metabolism

A61P 9/00 (2006.01) Drugs for disorders of the cardiovascular system

A61P 13/12 (2006.01) Drugs for disorders of the urinary system

A61P 17/12 (2006.01) Drugs for dermatological disorders

A61P 37/02 (2006.01) Drugs for immunological or allergic disorders

Event Publications

3 June 2010 PCT application entered the National Phase

  PCT publication WO2009/061445 Priority application(s): WO2009/061445

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2008325141-Methods of administering N- (5-tert-butyl-isoxazol-3-yl)-N'-{4-[7-(2-m orpholin4-yl-ethoxy)imidazo[2,1-b][1,3]benzothi azol-2-yl]phenyl}urea to treat proliferative disease

2008325122-Self-assembling micelle-like nanoparticles for systemic gene delivery